Evidence mapPaperPMID 42558396Full record

ReviewFrontiers in immunology2026

Reframing macrophage polarization through cholesterol efflux: an organelle-coupled immunometabolic model.

Ya Zou, Yun Lu, Lu Zhou, Qinchuan Li, Hua Wei, Yan Zhou, Shibo Lin, Xirui Guo, Shihao Yan, Hongju Wang and 2 more

Abstract readReview
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ya ZouDepartment of Clinical Pharmacology, Sichuan University affiliated Chengdu Second People's Hospital, Chengdu Second People's Hospital, West China School of Medicine, Sichuan University, Chengdu, China.
Yun LuDepartment of Clinical Pharmacology, Sichuan University affiliated Chengdu Second People's Hospital, Chengdu Second People's Hospital, West China School of Medicine, Sichuan University, Chengdu, China.
Lu ZhouDepartment of Clinical Pharmacology, Sichuan University affiliated Chengdu Second People's Hospital, Chengdu Second People's Hospital, West China School of Medicine, Sichuan University, Chengdu, China.
Qinchuan LiDepartment of Clinical Pharmacology, Sichuan University affiliated Chengdu Second People's Hospital, Chengdu Second People's Hospital, West China School of Medicine, Sichuan University, Chengdu, China.
Hua WeiDepartment of Clinical Pharmacology, Sichuan University affiliated Chengdu Second People's Hospital, Chengdu Second People's Hospital, West China School of Medicine, Sichuan University, Chengdu, China.
Yan ZhouDepartment of Clinical Pharmacology, Sichuan University affiliated Chengdu Second People's Hospital, Chengdu Second People's Hospital, West China School of Medicine, Sichuan University, Chengdu, China.
Shibo LinDepartment of Clinical Pharmacology, Sichuan University affiliated Chengdu Second People's Hospital, Chengdu Second People's Hospital, West China School of Medicine, Sichuan University, Chengdu, China.
Xirui GuoDepartment of Clinical Pharmacology, Sichuan University affiliated Chengdu Second People's Hospital, Chengdu Second People's Hospital, West China School of Medicine, Sichuan University, Chengdu, China.
Shihao YanDepartment of Clinical Pharmacology, Sichuan University affiliated Chengdu Second People's Hospital, Chengdu Second People's Hospital, West China School of Medicine, Sichuan University, Chengdu, China.
Hongju WangDepartment of Clinical Pharmacology, Sichuan University affiliated Chengdu Second People's Hospital, Chengdu Second People's Hospital, West China School of Medicine, Sichuan University, Chengdu, China.
Fangqing XieDepartment of Clinical Pharmacology, Sichuan University affiliated Chengdu Second People's Hospital, Chengdu Second People's Hospital, West China School of Medicine, Sichuan University, Chengdu, China.
Chun LiuDepartment of Clinical Pharmacology, Sichuan University affiliated Chengdu Second People's Hospital, Chengdu Second People's Hospital, West China School of Medicine, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Macrophages reside at the interface of immunity and metabolism, where their functional states are traditionally described by the M1/M2 polarization paradigm. However, this binary framework fails to capture the dynamic integration between inflammatory signaling and lipid metabolism that underlies macrophage behavior in chronic diseases. A central unresolved question is why macrophages, under sustained inflammatory and metabolic stress, progressively lose their capacity to maintain cholesterol homeostasis. Here, we propose a conceptual framework that is not merely a reinterpretation of existing data but a testable model: the macrophage polarization-efflux coupling axis, in which macrophage functional states are governed by the coordinated integration of lipid metabolism and organellar homeostasis, particularly the mitochondria-lysosome axis. Current evidence suggests that impaired cholesterol efflux may function as an active driver, rather than merely a downstream consequence, of macrophage dysfunction, based on evidence showing that genetic or pharmacological restoration of efflux actively repolarizes inflammatory macrophages toward a resolving phenotype. Lipid accumulation is reframed as a consequence of system-level failure arising from mismatched mitochondrial energy metabolism and lysosomal processing capacity. We further synthesize evidence demonstrating how transcriptional regulators, microRNA networks, epigenetic memory, and post-translational modifications converge to stabilize this dysfunctional state across diseases such as atherosclerosis and diabetic kidney disease. Importantly, emerging therapeutic strategies that restore organellar integrity and metabolic coordination show greater promise than approaches solely targeting inflammatory polarization. This integrative perspective shifts the focus from static phenotypic classification toward dynamic metabolic-organelle coupling, providing a unifying framework for understanding macrophage dysfunction and identifying novel therapeutic opportunities.

Indexed as

CholesterolMacrophage ActivationMacrophagesOrganellesAnimalsBiological TransportEnergy MetabolismHomeostasisHumansLipid MetabolismLysosomesMitochondriaCholesterolatherosclerosischolesterol effluxdiabetic kidney diseaseimmunometabolismmacrophage polarizationmitochondria-lysosome axisorganelle homeostasis

Identifiers

PMID42558396
PMCPMC13437365

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.